Topic

Lymphir

A collection of 1 issue

Citius Pharmaceuticals Upgraded to Buy with $9 Target

Citius Pharmaceuticals (CTXR) gets a Buy upgrade from D. Boral Capital with a $9 price target, driven by the anticipated commercialization of Lymphir.